Parkinson's Disease
Conditions
Interventions
Acupuncture Group:In addition to the baseline treatment, patients received acupuncture at the following acupoints: Sishenzhen (EX-HN1), Shenting (GV24), Yintang (EX-HN3), bilateral Shenmen (HT7), bila
Sham Acupuncture Group:In addition to the baseline treatment, patients received sham acupuncture at the same set of acupoints as the acupuncture group. Treatment was administered once per day on Monda
Sponsors
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
45 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Aged 45–80 years, both males and females are eligible. (2) Hoehn–Yahr stage 1–3. (3) Have been on anti-PD medication for at least six months, with a stable dose maintained for at least one month prior to enrollment. (4) Able to understand and voluntarily sign the informed consent form. (5) Meet the diagnostic criteria for PD with pain. (6) Visual Analog Scale (VAS) score between 1 and 6, indicating mild-to-moderate pain.
Exclusion criteria
Exclusion criteria: (1) Patients with severe cognitive impairment and hallucinations who are unable to cooperate with scale assessments. (2) Patients with severe comorbidities, including senile psychosis, epilepsy, malignant tumors, endocrine and metabolic diseases, or severe cardiac, pulmonary, hepatic, renal, or other organ-related diseases. (3) Participation in other clinical trials involving drugs, acupuncture, or other interventions within one month prior to enrollment in this study. (4) Inability to regularly take anti-PD medication due to adverse reactions or other reasons. (5) Patients who have previously undergone or plan to undergo deep brain stimulation therapy or rectal infusion of levodopa during the study period. (6) Female patients who are pregnant, breastfeeding, or planning to become pregnant in the near future. (7) Patients unable to cooperate with acupuncture treatment. (8) Patients requiring analgesic medications such as opioids or nonsteroidal anti-inflammatory drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| King's Parkinson's Disease Pain Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| PainDetect Questionnaire;Unified Parkinson's Disease Rating Scale;Parkinson's Disease Quality of Life Questionnaire - 39;Hamilton Depression Rating Scale;Somatosensory Evoked Potentials;Glial Fibrillary Acidic Protein;Tumor Necrosis Factor-a;S100 Calcium-Binding Protein B; | — |
Countries
China
Contacts
Public ContactZhuanglixing
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Outcome results
None listed